Lv7139
4960 积分 2022-11-08 加入
Updated Survival Outcome of Regorafenib, Ipilimumab, and Nivolumab in Refractory Microsatellite Stable Non-Liver Metastatic Colorectal Cancer: A Phase I Nonrandomized Clinical Trial
10天前
已完结
Regulatory T cells as crucial trigger and potential target for hyperprogressive disease subsequent to PD-1/PD-L1 blockade for cancer treatment
23天前
已完结
Hyperprogression during immunotherapy
25天前
已完结
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
1个月前
已完结
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic Non‒Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial
2个月前
已完结
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
2个月前
已完结
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
2个月前
已完结
Engineering focusing on cancer
4个月前
已完结
Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer – The PICCASSO phase I trial
5个月前
已完结
皖公网安备34019202002308
